Research News

Rucaparib Receives Breakthrough Therapy Designation from FDA

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have... 

OCRF Now Accepting Applications for 2016 Research Grants

We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.  MORE

Microenvironment Regulates Tumor Suppressor miRNA

Ernst Lengyel, MD, PhD (April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused...